Alpha Cognition

No. Alpha Cognition is a clinical-stage biopharmaceutical company that trades publicly. It does not manage third-party capital, maintain a fund structure, or allocate to external managers. The entity is an operating business developing a single drug candidate for Alzheimer's disease, not a wealth-management or family-office structure.

ALPHA-1062 is a prodrug of galantamine, the active ingredient in Razadyne, which is an approved acetylcholinesterase inhibitor used to treat mild-to-moderate Alzheimer's. As a prodrug, it is designed to convert into the active compound after absorption, potentially reducing the gastrointestinal side effects that cause many patients to discontinue galantamine therapy. The development strategy relies on the FDA's 505(b)(2) pathway, which permits the applicant to reference prior safety and efficacy data from the original approved drug.

The FDA issued a Complete Response Letter for the initial New Drug Application, requesting additional manufacturing data. Alpha Cognition resubmitted the application in February 2024. No approval has been granted as of the latest public disclosure. An FDA decision on the resubmitted application is the primary catalyst for the company.

As a publicly traded company, Alpha Cognition funds operations through equity sales in the capital markets. It does not raise capital through limited partner commitments, a fund-of-funds model, or family-office allocations. The burn rate is tied to regulatory and clinical-development milestones, with no diversified investment portfolio to offset risk.

No. The company holds no disclosed minority positions in portfolio companies, real-asset interests, or fund-of-fund commitments. Its balance sheet reflects cash reserves and operational assets associated with a pre-revenue biotech development program, not an investment portfolio.